Get the Stockscreener App
1.91
89.05%
0.8997
After Hours:
1.65
-0.26
-13.61%
Trinity Biotech Plc Adr stock is traded at $1.91, with a volume of 207.86M.
It is up +89.05% in the last 24 hours and up +157.66% over the past month.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
See More
Previous Close:
$1.0103
Open:
$2.17
24h Volume:
207.86M
Relative Volume:
50.57
Market Cap:
$4.31M
Revenue:
$71.39M
Net Income/Loss:
$-28.60M
P/E Ratio:
-0.5107
EPS:
-3.74
Net Cash Flow:
$-12.92M
1W Performance:
+114.20%
1M Performance:
+157.66%
6M Performance:
+151.32%
1Y Performance:
-24.51%
1-Day Range:
$1.54
$3.44
1-Week Range:
$0.8213
$3.44
52-Week Range:
$0.48
$3.44
Trinity Biotech Plc Adr Stock (TRIB) Company Profile
Name
Trinity Biotech Plc Adr
Sector
Industry
Phone
-
Address
-
Compare TRIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRIB
Trinity Biotech Plc Adr
|
1.91 | 21.05M | 71.39M | -28.60M | -12.92M | -3.74 |
|
ABT
Abbott Laboratories
|
129.28 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.15 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.52 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
91.98 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.18 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Trinity Biotech Plc Adr Stock (TRIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-15 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-03-15 | Initiated | Raymond James | Outperform |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jul-22-08 | Reiterated | Roth Capital | Buy |
| Mar-17-08 | Reiterated | Roth Capital | Buy |
| Dec-10-07 | Reiterated | Roth Capital | Buy |
| Oct-26-07 | Reiterated | Roth Capital | Buy |
View All
Trinity Biotech Plc Adr Stock (TRIB) Latest News
Trinity Biotech stock soars after NY regulatory approval for preeclampsia test - Investing.com
Trinity Biotech receives NY approval for preeclampsia test - Investing.com
Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service - GlobeNewswire Inc.
Trinity Biotech stock rises on successful CGM calibration-free trial - Investing.com
Trinity Biotech reports positive results for calibration-free CGM By Investing.com - Investing.com South Africa
Trinity Biotech reports positive results for calibration-free CGM - Investing.com
Trinity Biotech (TRIB) to Release Earnings on Wednesday - Defense World
Trinity Biotech launches preeclampsia testing service for maternal health By Investing.com - Investing.com South Africa
Trinity Biotech launches preeclampsia testing service for maternal health - Investing.com India
Trinity Biotech Plc Sponsored ADR Class A to Host Earnings Call - ACCESS Newswire
Cadence Bank (CADE) Stock: A Year of Market Fluctuations - investchronicle.com
Trinity Biotech receives WHO approval for offshore HIV test manufacturing - Investing.com
Trinity Biotech Appoints New Interim CFO - Investing.com India
Trinity Biotech stock hits 52-week low at $0.62 amid challenges - Investing.com
Trinity Biotech (NASDAQ:TRIB) Research Coverage Started at StockNews.com - Armenian Reporter
Trinity Biotech stock hits 52-week low at $0.72 amid challenges By Investing.com - Investing.com South Africa
Trinity Biotech stock hits 52-week low at $0.72 amid challenges - Investing.com
Trinity Biotech secures amended credit to fuel growth By Investing.com - Investing.com South Africa
Trinity Biotech secures amended credit to fuel growth - Investing.com India
Trinity Biotech secures $4m for CGM technology growth - Investing.com
Trinity Biotech Secures Additional $4 Million in Debt Financing to Advance Continuous Glucose Monitoring Technology and Transformation Plan - Nasdaq
Investor Network: Trinity Biotech Plc Sponsored ADR to Host Earnings Call - ACCESS Newswire
TRIBTrinity Biotech Announces Quarter 1 Financial Results - br.ADVFN.com
Trinity Biotech Announces Quarter 2 Results Revenues of US$36.3m and Operating Profit of US$2.3m - br.ADVFN.com
Trinity Biotech Announces Quarter 4 Financial Results EPS of 17.1 Cent per Share -- an Increase of 10.3% - br.ADVFN.com
Trinity Biotech Announces Quarter 3 Results; Revenues Increase to $35.6m; Operating Profit Increases 56% - br.ADVFN.com
Trinity Biotech stock hits 52-week low at $0.74 amid market challenges - Investing.com
Trinity Biotech Announces Quarter 3 Financial Results, Acquisition of Blood Bank Screening Business and FDA Approval of HIV-2... - br.ADVFN.com
Trinity Biotech reports leap in CGM system accuracy - Investing.com
Trinity Biotech secures US funding for HIV tests - Investing.com
Trinity Biotech faces US aid policy impact, PPP loan scrutiny - Investing.com
Trinity Biotech announces breakthrough in CGM technology - Investing.com
Trinity Biotech stock hits 52-week low at $0.74 amid challenges By Investing.com - Investing.com South Africa
Trinity Biotech advances HIV test manufacturing to offshore site - Investing.com
Trinity Biotech regains Nasdaq compliance - Investing.com
Trinity Biotech expands into oncology with EpiCapture buyout - Investing.com
Trinity Biotech advances next-gen glucose monitor - Investing.com India
Global Blood Testing Market Size & Outlook, 2024-2030 - Grand View Research
Trinity Biotech to Implement ADS Ratio Change By Investing.com - Investing.com India
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo - Yahoo Finance
TRIB News Today | Why did Trinity Biotech stock go up today? - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Investors in health-care stocks get rich as M&A booms - MarketWatch
Why Synta Pharmaceuticals Corp. (SNTA) May Be Worth Selling - Insider Monkey
Trinity Biotech Plc Adr Stock (TRIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.30%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):